Phototherapy in Young People With Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02448433|
Recruitment Status : Unknown
Verified May 2015 by Rébecca Robillard, University of Ottawa.
Recruitment status was: Recruiting
First Posted : May 19, 2015
Last Update Posted : May 19, 2015
Bright light therapy is an established treatment pathway for sleep and circadian disorders and evidence suggests that it has antidepressant effects. The underlying mechanisms of these antidepressant effects are not fully understood and results from previous studies are somewhat variable. One of the important limitations of previous depression studies has been the heterogeneity of samples in which bright light therapy has been administered.
The main aim of this study is to evaluate whether the antidepressant effects of phototherapy in young persons with depression are modulated by changes in the sleep-wake cycle. We hypothesize that more pronounce initial sleep-phase delay will predict better antidepressant response to phototherapy and that the magnitude of changes in depressive symptoms across the course of the intervention will correlate with changes in the sleep-wake cycle.
|Condition or disease||Intervention/treatment||Phase|
|Depression||Device: Phototherapy light-emitting glasses||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phototherapy in Young People With Depression; Investigating Associations Between Changes in Actigraphic Sleep-wake Profile and Depressive Symptoms|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||April 2017|
Device: Phototherapy light-emitting glasses
The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m^2) upon awakening and progressive shift to earlier wake-up times.
Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.
During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls.
Other Name: Re-timer
- Severity of Depression [ Time Frame: Between baseline and post (4 weeks) intervention ]Change in severity of depression as measured by the Quick Inventory of Depressive Symptomatology (QIDSA17-SR)
- Severity of Depression [ Time Frame: Score between baseline and follow up (8 weeks) ]Change in depression as measured by the Quick Inventory of Depressive Symptomatology (QIDSA17-SR)
- Associations between Changes in Sleep-Wake Profile and Changes in Severity of Depression [ Time Frame: Between baseline and post (4 weeks) intervention ]Associations between changes in sleep-wake profile (mean sleep onset time, offset time efficiency and acrophase), as measured by actigraphy, and change in depression severity as measured by the Quick Inventory of Depressive Symptomatology (QIDSA17-SR)
- Associations between Initial Sleep-Wake Profile and Changes in Severity of Depression [ Time Frame: Baseline and post (4 weeks) intervention ]Associations between the initial sleep-wake profile (mean sleep onset time, offset time efficiency and acrophase), as measured by actigraphy, and change in depression severity as measured by the Quick Inventory of Depressive Symptomatology (QIDSA17-SR)
- Subjective Sleep Quality [ Time Frame: Between baseline and post (4 weeks) intervention ]Change in Leeds Sleep Evaluation Questionnaire score
- Fatigue Severity [ Time Frame: Between baseline and post (4 weeks) intervention ]Change in Fatigue Severity Scale score
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02448433
|Contact: Rébecca Robillard, PhD||+1 613 722 6521 ext email@example.com|
|Australia, New South Wales|
|Brain and Mind Research Insitute, The University of Sydney||Suspended|
|Camperdown, New South Wales, Australia, 2050|
|Sleep and Depression Research Units, Institute of Mental Health Research, University of Ottawa||Recruiting|
|Ottawa, Ontario, Canada, K1Z 7K4|
|Contact: Rébecca Robillard, PhD +1 613 722 6521 ext 6279 firstname.lastname@example.org|